Results 231 to 240 of about 33,862 (271)
Imiquimod-Induced Vitiligo: An HLA Case Investigated. [PDF]
Dermatol Pract ConceptKlimi E.
europepmc +1 more source
Ginsenoside Rg3 Ameliorates Psoriasis-Like Dermatitis through Inhibition of NF-κB/NLRP3 Inflammasome Signaling and Regulating Th17/Treg Balance. [PDF]
Immun Inflamm DisGao L +6 more
europepmc +1 more source
Experimental Validation of an Immune Cell Infiltration Signature in Psoriasis: Translating Computational Modeling to In Vivo Efficacy. [PDF]
J Clin Lab AnalZheng T +7 more
europepmc +1 more source
Carbon dioxide laser ablation as an alternative or adjunct treatment of Bowenoid in situ carcinoma in five cats. [PDF]
J Feline Med SurgGoebel K, Musser ML, Pieper JB.
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Reactions Weekly, 2007
Imiquimod is an immune response-modifying agent that demonstrates potent antiviral and antitumour activity. Although it's use has been approved by the FDA (Food and Drug Administration) in the treatment of external genital and perianal warts, actinic keratosis on the face or scalp and superficial basal cell carcinomas, it has recently been tried to ...
Unal I., Ertam I.
+6 more sources
Imiquimod is an immune response-modifying agent that demonstrates potent antiviral and antitumour activity. Although it's use has been approved by the FDA (Food and Drug Administration) in the treatment of external genital and perianal warts, actinic keratosis on the face or scalp and superficial basal cell carcinomas, it has recently been tried to ...
Unal I., Ertam I.
+6 more sources
Current Opinion in Infectious Diseases, 2003
Imiquimod is the first member of a new class of immune response modifiers; it was first approved in 1997 for the topical treatment of external genital and perianal warts. It is an imidazoquinoline, a novel synthetic compound which is an immune response stimulator, enhancing both the innate and acquired immune pathways (particularly T helper cell type 1-
+6 more sources
Imiquimod is the first member of a new class of immune response modifiers; it was first approved in 1997 for the topical treatment of external genital and perianal warts. It is an imidazoquinoline, a novel synthetic compound which is an immune response stimulator, enhancing both the innate and acquired immune pathways (particularly T helper cell type 1-
+6 more sources